Key Details
| Catalog | MAS-0124-YJ18 |
| Applications | ELISA; Neut |
| Host | Mouse |
| Reactivity | B. anthracis |
| Clonality | Monoclonal |
| Conjugations | Conjugation could be customized |
| Sub CAT. | Applications | Clone | Conjugations | Endotoxin Level | Size | Quantity | |
|---|---|---|---|---|---|---|---|
| MAS-0124-YJ18-A | ELISA, Neut | 3A11 | |||||
| MAS-0124-YJ18-B | ELISA, Neut | 4D12 | |||||
| MAS-0124-YJ18-C | ELISA, Neut | 1A13 |
Overview
Properties
Target
Overview
| Description | Clones 3A11, 4D12 and 1A13 are Mouse monoclonal IgGs recognize B. anthracis PA. All these three antibodies have neutralization activity. 3A11 binds to a epitope located in domain 4 (aa 596-735), while 4D12 and 1A13 bind to epitopes located in domain 2 (aa 250-488). |
| Reactivity | B. anthracis |
| Applications | ELISA; Neut |
| Host | Mouse |
| Immunogen | Recombinant anthrax protective antigen expressed in E. coli. |
| Isotype |
3A11, 4D12: IgG1 1A13: IgG2a |
| Clonality | Monoclonal |
| Clone | 3A11; 4D12; 1A13 |
| Dilutions | ELISA: 0.1-1000 ng/mL |
Properties
| Expression Host | HEK293F/CHO |
| Conjugations | Conjugation could be customized |
| Purification | Protein A/G affinity purified is the regular method |
| Purity | SDS-PAGE> 95% |
| Endotoxin Level | Endotoxin level could be customized |
| Form | Liquid (frequently-used) or lyophilized |
| Concentration | About 1mg/ml. There are differences between batches. Special concentration could be customized. |
| Sterility | 0.2 μM filtered |
| Buffer | See the Datasheet |
| Storage | See the Datasheet |
Target
| Target | B. anthracis PA |
| Alternative Names | PA; PA83; Pag; PagA; Protective antigen; Bacillus anthracis; B. anthracis; Bacillus anthracis |
| Introduction | Anthrax toxins are composed of three distinct proteins, a protective antigen (PA), a lethal factor (LF) and an edema factor (EF). None of these proteins are toxic by themselves and several studies indicate that the anthrax toxin has the familiar A-B enzymatic binding structure, with PA acting as the binding domain and EF and/or LF acting as the active fragments. |
| Organism | Bacteria |
| Related Disease | Anthrax |
| Infections Route | Cutaneous; Inhalation; Gastrointestinal; Injection |
Online Inquiry